一项研究皮下度伐利尤单抗药代动力学和安全性的I期剂量递增和剂量扩展研究 (IMFINZI-subQ)
一项I期、多中心、剂量递增和剂量扩展研究,旨在探讨皮下注射度伐利尤单抗在成年实体瘤参与者中的药代动力学和安全性
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
研究概览
详细说明
This is a Phase I, multicentre study that will consist of 2 parts -
- Part 1: Dose Escalation
- Part 2: Dose Expansion
Part 1 may include participants with solid tumours - non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) or limited-stage small cell lung cancer (LS-SCLC). It will further consist of 2 planned dose levels of SC durvalumab - Dose level 1 (DL1) and Dose level 2 (DL2).
Part 2 will include participants with unresectable HCC. It will be initiated once a dose has been identified based on Part 1.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
学习地点
-
-
-
Batumi、乔治亚州、6010
- 招聘中
- Research Site
-
Tbilisi、乔治亚州、0114
- 招聘中
- Research Site
-
Tbilisi、乔治亚州、0112
- 招聘中
- Research Site
-
-
-
-
-
Tainan、台湾、73657
- 招聘中
- Research Site
-
Taipei、台湾、112
- 撤销
- Research Site
-
Taipei、台湾、110
- 招聘中
- Research Site
-
Taoyuan、台湾、333
- 撤销
- Research Site
-
-
-
-
-
Brzozów、波兰、36-200
- 招聘中
- Research Site
-
Koszalin、波兰、75-581
- 招聘中
- Research Site
-
Lublin、波兰、20-090
- 招聘中
- Research Site
-
Olsztyn、波兰、10-357
- 招聘中
- Research Site
-
Przemyśl、波兰、37-700
- 招聘中
- Research Site
-
-
-
-
-
Fitzroy、澳大利亚、3065
- 撤销
- Research Site
-
St Albans、澳大利亚、3021
- 撤销
- Research Site
-
Woolloongabba、澳大利亚、4102
- 撤销
- Research Site
-
-
-
-
-
Seongnam-si、韩国、13620
- 招聘中
- Research Site
-
Seoul、韩国、06351
- 招聘中
- Research Site
-
Seoul、韩国、5505
- 招聘中
- Research Site
-
Seoul、韩国、03722
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of ≥ 12 weeks at enrolment.
- Adequate organ and marrow function.
- Minimum body weight > 30 kg.
Part 1 only:
Locally Advanced Unresectable (Stage III) NSCLC Participants -
- Histological or cytological documented evidence of NSCLC (locally advanced, unresectable, Stage III).
- Must have received at least 2 cycles of platinum-based chemotherapy concurrent with definitive radiation therapy.
- Have not progressed following definitive concurrent chemoradiation.
LS-SCLC Participants -
- Histologically or cytologically documented LS-SCLC (Stage I-III).
- Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to enrolment.
- Have not progressed following definitive concurrent chemoradiation.
Part 1 and 2:
Unresectable HCC Participants -
- Unresectable HCC based on histopathological confirmation.
- No prior systemic therapy for unresectable HCC.
- Must not be eligible for locoregional therapy for unresectable HCC.
- Child-Pugh Score class A.
- Measurable disease as defined by RECIST v1.1.
Exclusion Criteria:
- Active or prior documented autoimmune disease requiring systemic treatment.
- Uncontrolled infection (including human immunodeficiency virus [HIV], hepatitis B or C).
- Prior exposure to immune checkpoint inhibitors.
Part 1 only:
Locally Advanced Unresectable (Stage III) NSCLC Participants -
- Mixed SCLC and NSCLC histology.
- Active pneumonitis or interstitial lung disease requiring systemic therapy.
LS SCLC Participants -
- Mixed SCLC and NSCLC histology.
- Extensive-stage disease.
- History of Grade ≥ 2 pneumonitis.
Part 1 and 2:
Unresectable HCC Participants -
- Hepatic encephalopathy.
- Uncontrolled ascites.
- Active gastrointestinal (GI) bleeding.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1: SC Durvalumab DL1
Participants will receive DL1 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
其他名称:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
|
实验性的:Part 1: SC Durvalumab DL2
Participants will receive DL2 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
其他名称:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
|
实验性的:Part 2: Expansion Cohort, SC Durvalumab Dose Level X
Participants will receive dose level X (determined from data analysis in Part 1) of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
其他名称:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area under the concentration-time curve
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the AUC of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Observed lowest concentration before the next dose is administered (Ctrough)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Ctrough of SC durvalumab |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Area under the concentration-time curve from time 0 to last quantifiable concentration (AUClast)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the AUClast of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Maximum observed concentration (Cmax)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Cmax of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Time to reach maximum concentration following drug administration (tmax)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the tmax of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Terminal elimination half-life (t1/2λz)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the t1/2λz of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Total body clearance/apparent total body clearance (CL[/F])
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the CL(/F) of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Apparent volume of distribution based on the terminal phase volume (Vz[/F])
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the VZ(/F) of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Average drug concentration over a dosing interval (Cavg)
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Cavg of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Serum concentration of durvalumab
大体时间:From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the serum concentration of SC durvalumab at specified timepoints. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Number of participants with adverse events (AEs)
大体时间:Up to Survival Follow-up (approximately 17 months)
|
To assess the safety and tolerability of SC durvalumab. |
Up to Survival Follow-up (approximately 17 months)
|
|
Number of participants with dose-limiting toxicities (DLTs)
大体时间:Up to Survival Follow-up (approximately 17 months)
|
To assess the safety and tolerability of SC durvalumab. |
Up to Survival Follow-up (approximately 17 months)
|
合作者和调查者
赞助
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- D907HC00001
- 2025-521639-34-00 (其他标识符:EU CT number)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.